Charles River Laboratories International Inc (NYSE:CRL)
$ 214.2 25.52 (13.53%) Market Cap: 10.95 Bil Enterprise Value: 13.50 Bil PE Ratio: 25.59 PB Ratio: 2.97 GF Score: 87/100

Charles River Laboratories International Inc at Barclays Global Healthcare Conference Transcript

Mar 15, 2023 / 02:15PM GMT
Release Date Price: $194.9 (-4.94%)
Luke England Sergott
Barclays Bank PLC, Research Division - Research Analyst

All right. Good morning, everybody. My name is Luke Sergott. I cover Life Sciences Tools and Diagnostics here at Barclays. With me today, it's my pleasure to have James Foster, CEO of Charles River, also known Jim Foster, whatever preference is.

Questions & Answers

Luke England Sergott
Barclays Bank PLC, Research Division - Research Analyst

So a lot to dig in here. So a lot of interesting topics to cover, but can we start off first talking about the [SAP] exposure and then the impacts that you're seeing from the customer base? Have you guys broken that out by the revs, I think you had something in your deck on it, but just anything that you're seeing there?

James C. Foster;
Charles River Laboratories International, Inc. - Chairman, CEO & President

Not seeing anything adverse. I don't just kind of (inaudible) from clients. We see saying all is good. So we don't expect that's going to have an impact on us.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot